Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
about
Challenges in translating endpoints from trials to observational cohort studies in oncologyMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerTime-dependent endpoints as predictors of overall survival in multiple myelomaStrategies for modern biomarker and drug development in oncology.Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsAnthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsCYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Multiple treatment comparison meta-analyses: a step forward into complexity.Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.In the end what matters most? A review of clinical endpoints in advanced breast cancer.Bevacizumab in the treatment of metastatic breast cancer: friend or foe?Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.Targeting angiogenesis in metastatic breast cancerThe role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerCorrelation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.Benefit-risk assessment of bevacizumab in the treatment of breast cancer.Sorafenib in locally advanced or metastatic breast cancer.A review of health technology appraisals: case studies in oncology.Bioinformatics advances for clinical biomarker development.Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.Clinical trials of interventional oncology-moving from efficacy to outcomes.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
P2860
Q26746190-F6EFDEAB-C20D-4F2C-B843-9CCB0F9F3B12Q26860469-1349DFBA-B5F3-42B8-955C-70A2ED8C74C8Q30538040-C7BD1A8A-AEEF-4048-B14D-43896099399CQ30590270-DC0B84F9-3046-427E-A9B0-8464FBC0EB09Q33600372-87E75C46-113C-45B1-BFB2-BD8D51A91EECQ33729389-38279816-0667-477F-9E53-BC63C2C3F3D2Q33800697-D48B2887-4688-4ED6-8FE3-DAC83BAAC4C9Q33898741-98D0FB13-B766-4FC3-B958-2F799C5D1DDBQ34040130-339F61FC-14D8-485D-A173-02A02EB39B3BQ35004750-37FA6598-3273-455B-9D2E-727C350EB987Q35009604-7D1F10D3-6EFF-4796-8EB2-3AA683EC53C7Q35089776-2017B766-16D4-49CF-B30F-4D7F28A5A54CQ35223628-22DBB123-8C76-423B-A37D-386589C6DAC4Q35223631-C4E746EF-57B4-4C75-A999-E3FB8D68C8E8Q35584322-E5701125-13CE-4662-9F8C-7DCA2FCED27DQ35696743-7159A586-F398-4365-BB5B-B7324E691592Q35714606-05491E12-E151-4F15-98E2-E361708E2B2AQ35820575-32614BF7-9EB0-4434-9E2B-7A9C6D9959DCQ36102859-6E76341C-A005-4EF7-A673-6AFBE35AABA2Q36174876-2FB53E18-8E24-49B9-9324-FBB1BDFA27E2Q36182795-14A4C36D-234B-4D1B-9DA2-DC5CC562D81CQ36405660-BCB67978-3DBB-4C96-AD16-EDB123912AADQ36454797-9A52DB92-C767-4C46-A10C-00D9CCA1FFC4Q36706109-20E9F44C-04E6-4E2B-90AB-C39F118A673CQ37275076-AB2A8A8C-A23E-414B-97A5-D30AA1A034FAQ37292020-56154A24-CF6A-42EA-85E4-C01DFF3166BBQ37477489-00DD8813-8572-434E-9883-A69CE96871B6Q37698439-628D3A31-80BA-45B5-BAEC-1ACF9A000448Q37955095-E423FB9A-ABC1-4A14-AA27-136A5B885C78Q37963955-140B1CD2-9B2F-43AE-B1E2-9962AD9CDE30Q38012156-F12263A6-EDA3-4774-85C4-867776B724ECQ38070022-C4C7AB98-93D2-4EA1-8368-41DD56A69430Q38088378-55BA3808-F554-4049-9D92-725118A541B5Q38209463-2D4AF2BA-893B-4B4A-B99D-2F4009C0702AQ38228850-01F86350-5C11-4C15-BC08-5FB09BA4650EQ38259501-D2EEA929-40C0-4AF5-8CF5-7F2F0CF403E2Q38261859-AFBE0D42-69E8-4E19-90A6-39A653FB2594Q38285540-9BA6DFB0-0EA2-48BF-9FF4-7249CA512FDFQ38636718-AA4D9C27-5EF7-4418-BF9F-5DD7A8C1CCAAQ38720644-60A7AD42-E4B9-4019-BBFC-AF9944F3C05E
P2860
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Progression-free survival as s ...... colorectal cancer literature.
@en
Progression-free survival as s ...... colorectal cancer literature.
@nl
type
label
Progression-free survival as s ...... colorectal cancer literature.
@en
Progression-free survival as s ...... colorectal cancer literature.
@nl
prefLabel
Progression-free survival as s ...... colorectal cancer literature.
@en
Progression-free survival as s ...... colorectal cancer literature.
@nl
P2093
P2860
P356
P1433
P1476
Progression-free survival as s ...... colorectal cancer literature.
@en
P2093
P2860
P356
10.1093/ANNONC/MDP523
P577
2009-11-09T00:00:00Z